7,000 Shares in Immunocore Holdings plc (NASDAQ:IMCR) Acquired by Connective Portfolio Management LLC

Connective Portfolio Management LLC purchased a new position in Immunocore Holdings plc (NASDAQ:IMCR) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 7,000 shares of the company’s stock, valued at approximately $218,000.

Other hedge funds have also made changes to their positions in the company. Tidal Investments LLC bought a new stake in Immunocore during the 1st quarter valued at $423,000. China Universal Asset Management Co. Ltd. raised its stake in Immunocore by 69.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,621 shares of the company’s stock valued at $430,000 after acquiring an additional 2,721 shares in the last quarter. Nan Fung Group Holdings Ltd bought a new stake in Immunocore during the 1st quarter valued at $439,000. DNB Asset Management AS raised its stake in Immunocore by 35.0% during the 2nd quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock valued at $244,000 after acquiring an additional 1,868 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Immunocore during the 2nd quarter valued at $303,000. Institutional investors own 84.50% of the company’s stock.

Analysts Set New Price Targets

IMCR has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research note on Tuesday, September 17th. JPMorgan Chase & Co. cut their price objective on Immunocore from $70.00 to $66.00 and set an “overweight” rating for the company in a report on Wednesday, July 10th. Needham & Company LLC cut their price objective on Immunocore from $81.00 to $78.00 and set a “buy” rating for the company in a report on Tuesday, September 17th. Oppenheimer restated an “outperform” rating and issued a $89.00 price objective (up previously from $87.00) on shares of Immunocore in a report on Friday, August 9th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a report on Monday, September 9th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $80.40.

Immunocore Trading Down 1.0 %

Shares of Immunocore stock traded down $0.32 on Wednesday, reaching $30.25. 11,208 shares of the company were exchanged, compared to its average volume of 556,411. The stock has a fifty day moving average price of $34.70 and a 200-day moving average price of $43.65. The firm has a market capitalization of $1.51 billion, a price-to-earnings ratio of -25.06 and a beta of 0.72. The company has a current ratio of 5.17, a quick ratio of 5.15 and a debt-to-equity ratio of 1.31. Immunocore Holdings plc has a fifty-two week low of $29.72 and a fifty-two week high of $76.98.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.25. The firm had revenue of $75.40 million for the quarter, compared to analyst estimates of $74.58 million. Immunocore had a negative return on equity of 14.68% and a negative net margin of 19.16%. Immunocore’s quarterly revenue was up 26.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.37) earnings per share. On average, analysts expect that Immunocore Holdings plc will post -1.79 EPS for the current year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.